A detailed history of Royal Bank Of Canada transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 5,778 shares of HBIO stock, worth $12,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,778
Previous 6,369 9.28%
Holding current value
$12,538
Previous $18,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.64 - $3.54 $1,560 - $2,092
-591 Reduced 9.28%
5,778 $15,000
Q2 2024

Aug 14, 2024

BUY
$2.77 - $4.63 $13,664 - $22,839
4,933 Added 343.52%
6,369 $18,000
Q1 2024

Nov 05, 2024

SELL
$4.02 - $5.39 $19,830 - $26,588
-4,933 Reduced 77.45%
1,436 $6,000
Q1 2024

May 15, 2024

SELL
$4.02 - $5.39 $47,657 - $63,898
-11,855 Reduced 89.2%
1,436 $6,000
Q4 2023

Feb 14, 2024

BUY
$4.0 - $5.49 $27,612 - $37,897
6,903 Added 108.06%
13,291 $71,000
Q3 2023

Nov 14, 2023

BUY
$4.0 - $5.82 $7,760 - $11,290
1,940 Added 43.62%
6,388 $27,000
Q2 2023

Aug 14, 2023

BUY
$4.19 - $6.16 $18,616 - $27,368
4,443 Added 88860.0%
4,448 $24,000
Q1 2023

May 15, 2023

SELL
$2.45 - $4.22 $2 - $4
-1 Reduced 16.67%
5 $0
Q4 2022

Feb 14, 2023

SELL
$2.12 - $2.86 $4 - $5
-2 Reduced 25.0%
6 $0
Q2 2022

Aug 15, 2022

SELL
$3.28 - $6.42 $7,891 - $15,446
-2,406 Reduced 99.67%
8 $0
Q1 2022

May 16, 2022

SELL
$5.16 - $7.14 $29,143 - $40,326
-5,648 Reduced 70.06%
2,414 $15,000
Q4 2021

Feb 14, 2022

BUY
$6.37 - $8.18 $22,995 - $29,529
3,610 Added 81.09%
8,062 $56,000
Q3 2021

Nov 15, 2021

BUY
$6.98 - $8.47 $10,016 - $12,154
1,435 Added 47.56%
4,452 $31,000
Q2 2021

Aug 16, 2021

BUY
$5.44 - $8.4 $16,412 - $25,342
3,017 New
3,017 $25,000

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $90.4M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.